Johnson & Johnson’s vaccine has been associated with an elevated risk of thrombosis with thrombocytopenia syndrome.

The new guidelines emphasize the importance of equal access to care among all patient populations, regardless of race or gender. 

The new study, published in the Journal of Vascular Surgery, evaluated outcomes after bypass surgery and endovascular therapy. 

It does increase certain risks, researchers found—but it can also be a valuable treatment option. 

The new treatment, still being tested in mice models, showed potential to help prevent future cardiovascular events in patients with vascular disease.

Thoracic endovascular aortic repair, researchers wrote, "could be safely preformed across a wide range of hospitals regardless of their volume status."

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin. 

The company's new imaging platform simultaneously performs intravascular ultrasound and optical coherence tomography, the two most commonly used modalities.

The study included data from more than 580,000 patients.